Pharmacy Benefits Management

September 30, 2020

Tykerb Generic Launched

September 30, 2020 – Lupin Pharmaceuticals has announced the launch of its generic version of Novartis’s Tykerb® (lapatinib) 250mg tablets. Lapatinib is indicated for the
September 28, 2020

Xeljanz Receives New Pediatric Indication

September 28, 2020 – The U.S. FDA has approved a new indication for Xeljanz® (tofacitinib), manufactured by Pfizer, to treat patients who are at least two years old and have active
September 27, 2020

Fetroja Receives New Indication for Pneumonia

September 27, 2020 – The U.S. FDA has approved a new indication for Fetroja® (cefiderocol), manufactured by Shionogi. The drug is now indicated to treat patients 18 years